Anti-CDKN2A/p16INK4a antibody [EPR20418],Abcam,AB211542

Anti-CDKN2A/p16INK4a antibody [EPR20418] (ab211542) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt (Intra), ICC/IF, IP, WB in mouse samples. Anti-CDKN2A/p16INK4a antibody [EPR20418] (ab211542) has been cited over 83 times in peer reviewed journals and is trusted by the scientific community. Abcams high quality manufacturing and validation processes ensure Anti-CDKN2A/p16INK4a antibody [EPR20418] (ab211542) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-CDKN2A/p16INK4a antibody [EPR20418] (ab211542) has 8 independent reviews from customers. Anti-CDKN2A/p16INK4a antibody [EPR20418] (ab211542) specifically detects CDKN2A/p16INK4a (UniProt ID: P51480; Molecular weight: 18kDa) and is sold in a convenient trial size to enable initial testing (20 uL) and larger sizes for subsequent scaling up experiments (100 uL and 1 mL). Conjugation-ready, carrier free format available for antibody clone EPR20418 - ab23242 . CDKN2A, also known as p16INK4a, is a crucial tumor suppressor gene involved in cell cycle regulation and cancer development. It encodes the p16INK4a protein, which inhibits cyclin-dependent kinases (CDKs) 4 and 6, preventing the phosphorylation of the retinoblastoma protein (Rb) and halting cell cycle progression from the G1 to the S phase. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .